NOVO NORDISK: EXPECTS U.S. FDA DECISION ON SELECT EXPANDED LABEL BY END OF FIRST HALF OF 2024
Novo Nordisk: Expects U.s. Fda Decision On Select Expanded Label…
![Reuters logo](/images/reuters.jpg)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
970 DKK | -0.34% |
|
+0.41% | +38.95% |
11:17am | Novo Nordisk's Main Owner Leads $100 Million Financing of Biotech Firm Asceneuron | DJ |
09:00am | Novo owner backs Swiss biotech Asceneuron in $100 million round | RE |
NOVO NORDISK: EXPECTS U.S. FDA DECISION ON SELECT EXPANDED LABEL BY END OF FIRST HALF OF 2024
1st Jan change | Capi. | |
---|---|---|
+38.95% | 631B | |
+62.11% | 856B | |
-4.15% | 359B | |
+15.47% | 325B | |
+9.10% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.96% | 177B | |
+2.28% | 165B | |
+2.41% | 126B |